🚀 VC round data is live in beta, check it out!
Mycodern Valuation Multiples
Discover revenue and EBITDA valuation multiples for Mycodern and similar public comparables like BioRegenx, Pharmena, PMGC Holdings, Arctic Bioscience and more.
Mycodern Overview
About Mycodern
Mycodern SA is committed to providing the highest quality functional food and innovative dietary supplement products.
Founded
1999
HQ
Employees
7
Website
Financials (FY)
EV
$12M
Mycodern Financials
Mycodern reported last fiscal year revenue of — and negative EBITDA of ($10K).
In the same fiscal year, Mycodern generated ($10K) in EBITDA losses and had net loss of ($20K).
Mycodern P&L
In the most recent fiscal year, Mycodern reported revenue of — and EBITDA of ($10K).
Mycodern expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | — | XXX | ($10K) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($20K) | XXX | XXX | XXX |
| Net Debt | — | — | $566K | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Mycodern Stock Performance
Mycodern has current market cap of $12M, and enterprise value of $12M.
Market Cap Evolution
Mycodern's stock price is $0.18.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $12M | $12M | 0.3% | XXX | XXX | XXX | $-0.00 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialMycodern Valuation Multiples
Mycodern trades at (1221.4x) EV/EBITDA.
Mycodern Financial Valuation Multiples
As of April 12, 2026, Mycodern has market cap of $12M and EV of $12M.
Equity research analysts estimate Mycodern's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Mycodern has a P/E ratio of (583.0x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $12M | XXX | $12M | XXX | XXX | XXX |
| EV (current) | $12M | XXX | $12M | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (1221.4x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (611.7x) | XXX | XXX | XXX |
| P/E | — | XXX | (583.0x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | 83765.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Mycodern Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Mycodern Margins & Growth Rates
Mycodern's revenue in the last fiscal year declined by (100%).
Mycodern's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.0M for the same period.
Mycodern Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | (100%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (100%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Mycodern Public Comps
See public comps and valuation multiples for other Nutraceuticals & Cosmeceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| BioRegenx | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharmena | XXX | XXX | XXX | XXX | XXX | XXX |
| PMGC Holdings | XXX | XXX | XXX | XXX | XXX | XXX |
| Arctic Bioscience | XXX | XXX | XXX | XXX | XXX | XXX |
| Simris Group | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Mycodern M&A Activity
Mycodern acquired XXX companies to date.
Last acquisition by Mycodern was on XXXXXXXX, XXXXX. Mycodern acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Mycodern
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialMycodern Investment Activity
Mycodern invested in XXX companies to date.
Mycodern made its latest investment on XXXXXXXX, XXXXX. Mycodern invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Mycodern
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Mycodern
| When was Mycodern founded? | Mycodern was founded in 1999. |
| Where is Mycodern headquartered? | Mycodern is headquartered in Poland. |
| How many employees does Mycodern have? | As of today, Mycodern has over 7 employees. |
| Is Mycodern publicly listed? | Yes, Mycodern is a public company listed on Frankfurt Stock Exchange. |
| What is the stock symbol of Mycodern? | Mycodern trades under GY3 ticker. |
| When did Mycodern go public? | Mycodern went public in 2023. |
| Who are competitors of Mycodern? | Mycodern main competitors are BioRegenx, Pharmena, PMGC Holdings, Arctic Bioscience. |
| What is the current market cap of Mycodern? | Mycodern's current market cap is $12M. |
| Is Mycodern profitable? | No, Mycodern is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.